Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American ...

Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...